Grace Therapeutics (GRCE) Total Non-Current Liabilities (2019 - 2026)

Grace Therapeutics has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $1.9 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 59.76% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (down 59.76% YoY), while the FY2026 annual figure was $2.8 million, down 34.98% from the prior year.
• Total Non-Current Liabilities came in at $1.9 million for Q2 2026 at Grace Therapeutics, down from $2.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $20.7 million in Q3 2022 to a low of $1.9 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $8.5 million, with a median of $6.9 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities surged 1188.16% in 2022 and slumped 61.4% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $20.1 million in 2022, then slumped by 59.3% to $8.2 million in 2023, then slumped by 35.1% to $5.3 million in 2024, then slumped by 32.2% to $3.6 million in 2025, then tumbled by 48.22% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.9 million in Q2 2026, $2.8 million in Q1 2026, and $3.6 million in Q4 2025.